Stock listing

NASDAQ:SLDB Solid Biosciences Inc. Stock

Home listing (NASDAQ) of Solid Biosciences Inc.

Follow Solid Biosciences Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:SLDB

$6.25 USD -0.10 (-1.6%)

Close on Nov 20, 2026

Past year +40.1% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$6.20 – $6.53 USDNov 20, 2026
Volume
1.56M sharesNov 20, 2026
Market cap
$697.6M USDAt the close on Nov 20, 2026 · price × 111.6M shares outstanding
52-week range
$4.45 – $11.45 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$9.44M USDMedian day 1.19M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Solid Biosciences Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:SLDB · Home$6.25 USD-0.10 (-1.6%)1,558,939$6.34$6.53$6.195$6.35Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:SLDB · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$6.25-0.10-1.6%$6.34$6.53$6.1951,558,939
$6.35+0.12+1.9%$6.22$6.425$6.081,206,527
$6.23-0.25-3.9%$6.48$6.57$6.101,133,949
$6.48-0.36-5.3%$6.76$6.94$6.45872,638
$6.84-0.16-2.3%$7.00$7.05$6.565975,452
$7.00-0.60-7.9%$7.59$7.59$6.971,322,914
$7.60+0.43+6.0%$7.26$7.855$7.1791,957,911
$7.17+0.15+2.1%$6.88$7.32$6.8451,721,858
$7.02+0.43+6.5%$6.87$7.245$6.5852,373,416
$6.59+0.41+6.6%$6.18$6.73$6.181,426,523
$6.18-0.34-5.2%$6.60$6.62$6.011,435,885
$6.52+0.24+3.8%$6.59$6.68$6.2281,058,635
$6.28+0.28+4.7%$6.09$6.32$6.061770,148
$6.00-0.20-3.2%$6.28$6.305$5.831,129,328
$6.20-0.19-3.0%$6.30$6.43$6.02873,117
$6.39-0.09-1.4%$6.51$6.65$6.27964,669
$6.48+0.29+4.7%$6.08$6.525$5.961,510,803
$6.19+0.38+6.5%$5.84$6.23$5.7651,551,480
$5.81-0.11-1.9%$6.00$6.09$5.741,070,933
$5.92-0.27-4.4%$6.12$6.23$5.78769,967
$6.19-0.22-3.4%$6.33$6.52$6.0951,217,098
$6.41+0.01+0.2%$6.46$6.58$6.321,147,634
$6.40+0.48+8.1%$5.93$6.52$5.861,465,155
$5.92+0.39+7.1%$5.62$6.04$5.561,847,907
$5.53-0.21-3.7%$5.73$5.825$5.481,401,831
$5.74+0.275+5.0%$5.55$5.835$5.3852,033,374
$5.465-0.355-6.1%$5.66$5.71$5.402,378,470
$5.82-0.89-13.3%$6.65$6.65$5.702,869,736
$6.71-0.16-2.3%$6.85$6.93$6.69601,311
$6.87+0.05+0.7%$6.81$7.045$6.755726,812
$6.82-0.03-0.4%$6.75$6.88$6.6351,308,109
$6.85-0.07-1.0%$6.76$6.975$6.69744,708
$6.92-0.14-2.0%$7.11$7.11$6.651,188,692
$7.06+0.21+3.1%$6.88$7.205$6.771,372,173
$6.85-0.13-1.9%$7.14$7.26$6.781,198,189
$6.98-0.25-3.5%$7.14$7.245$6.911,582,201
$7.23+0.07+1.0%$7.24$7.54$7.161,711,185
$7.16-0.12-1.6%$7.26$7.325$6.901,392,322
$7.28-0.01-0.1%$7.14$7.345$7.0951,413,513
$7.29-0.19-2.5%$7.53$7.54$7.151,420,530
$7.48-0.54-6.7%$7.95$8.00$7.351,349,278
$8.02-0.90-10.1%$8.89$8.91$8.0011,088,231
$8.92+0.38+4.4%$8.67$8.955$8.561,305,487
$8.54-0.37-4.2%$9.03$9.03$8.5251,170,809
$8.91+0.04+0.5%$8.87$8.97$8.6354,090,597
$8.87+0.15+1.7%$8.94$8.97$8.601,193,532
$8.72+0.35+4.2%$8.62$8.755$8.2652,256,406
$8.37-0.37-4.2%$8.69$8.69$8.161,514,418
$8.74+0.04+0.5%$8.82$9.109$8.711,025,185
$8.70-0.37-4.1%$9.205$9.365$8.6551,113,857
$9.07-0.47-4.9%$9.36$9.36$9.01855,917
$9.54-0.39-3.9%$9.77$9.95$9.53646,346
$9.93-0.32-3.1%$10.00$10.09$9.58742,815
$10.25-0.17-1.6%$10.20$10.48$10.20495,327
$10.42+0.135+1.3%$10.30$10.46$10.05728,483
$10.29+0.405+4.1%$9.92$10.44$9.75894,270
$9.88+0.30+3.1%$9.44$9.95$9.37803,305
$9.58-0.19-1.9%$9.73$9.73$9.37686,620
$9.77-0.36-3.6%$10.02$10.10$9.72621,524
$10.13+0.41+4.2%$10.03$10.27$9.89988,931
$9.72-0.17-1.7%$9.84$9.85$9.60594,174
$9.89+0.73+8.0%$9.33$9.90$9.331,260,522
$9.16-0.14-1.5%$9.28$9.28$8.861,114,777
$9.30+0.20+2.2%$9.34$9.665$9.23790,365
$9.10-0.64-6.6%$9.51$9.57$8.811,076,892

Splits

1 split · NASDAQ:SLDB · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
Ticker
NASDAQ:SLDB
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Solid Biosciences Inc. news

Solid Biosciences Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 108 in all · newest Nov 10, 2026 · oldest 2019
Calls
1 call with a replay · 1 with a transcript · latest Apr 27, 2022
Decks
14 decks · latest September 2026

Where Solid Biosciences Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:SLDB · Home listing · This pageNASDAQUnited StatesUSD
BOATS:SLDBBOATSUnited StatesUSD

Valuation

Price/book 2.0× against a median of 4.1×: 4th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$368.3M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
Negative EBITDA
Price/book
2.0×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.1×
Beta vs S&P 500
1.85

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Solid Biosciences Inc. · NASDAQ:SLDBUS$697.6MUS$368.3Mn/an/an/a2.0×n/a0.1×1.85
Monte Rosa Therapeutics, Inc. · NASDAQ:GLUEUS$738.3MUS$196.8Mn/a2.8×n/a1.5×−186.2%0.1×0.92
Aimed Bio Inc. · KRX:0009K0US$726.5MUS$657.3M25.2×13.2×34.0×4.8×57.8%0.0×n/a
Aura Biosciences, Inc. · NASDAQ:AURAUS$715.0MUS$433.9Mn/an/an/a2.5×n/a0.1×1.07
Attovia Therapeutics, Inc. · NASDAQ:ATTOUS$689.3MUS$297.2Mn/a220×n/a1.7×n/a0.0×n/a
Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRXUS$681.2MUS$549.9Mn/a14.3×n/a4.2×−161.8%0.3×1.15
CARsgen Therapeutics Holdings Ltd. · HKEX:2171US$676.0MUS$477.2Mn/a25.4×n/a4.1×−77.9%0.1×n/a
Philogen SpA · MIL:PHILUS$672.3MUS$532.7M2.7×1.5×n/a1.6×71.8%0.0×n/a
Nuvectis Pharma, Inc. · NASDAQ:NVCTUS$666.8MUS$526.1Mn/an/an/a5.3×n/a0.0×0.84
Sun Pharma Advanced Research Co. Ltd. · NSE:SPARCUS$665.9MUS$519.0M3.8×2.5×2.9×4.3×84.7%0.0×n/a
Oscotec Inc. · KRX:039200US$664.8MUS$664.8M11.6×6.3×n/a4.5×54.0%0.0×n/a
Median of the othersUS$678.6MUS$522.6M7.7×9.7×18.5×4.1×54.0%0.0×1.00

Forecasts

10 strong buy · 5 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
18.71 USD · Analysts' mean
EPS, year to Dec 2026
-1.67 · 13 analysts

Team and board

Officers

OfficerRole
Bo CumboPresident and CEO
Lynne SullivanChief Financial Officer at Unity Biotechnology
Sukumar NagendranPresident, Head of Research & Development, Taysha Gene Therapies

Board

DirectorRole
Ian F. SmithChairman of the Board
Clare KahnBoard Member
Georgia KerestyBoard Member
Martin FreedBoard Member

Events

Calls

CallWhenStatus
Solid Biosciences (NASDAQ:SLDB) Q1 2022 Earnings CallWed, Apr 27, 2022 · 8:00 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 4, 2026 · After close−5.2%
Q2 2026Aug 6, 2026 · After close−3.7%
Q1 2026May 13, 2026−1.2%
Q4 2025Mar 19, 2026 · After close−1.3%
Q3 2025Nov 3, 2025 · After close−15.3%
Q2 2025Aug 12, 2025 · After close+10.6%
Q1 2025May 15, 2025 · After close+7.0%
Q4 2024Mar 11, 2025 · Before open+10.2%
Q3 2024Nov 6, 2024 · After close−6.0%
Q2 2024Aug 13, 2024 · After close+14.5%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open−2.7%
Q4 2023Mar 13, 2024 · Before open+7.3%
Q3 2023Nov 8, 2023 · After close−23.7%
Q2 2023Aug 14, 2023 · After close−2.5%
Q1 2023May 11, 2023 · Before open+3.9%
Q4 2022Mar 23, 2023 · Before open−0.3%
Q3 2022Nov 10, 2022 · Before open+2.2%
Q2 2022Aug 11, 2022 · Before open+3.6%
Q1 2022Apr 27, 2022 · Before open−17.0%
Q4 2021Mar 14, 2022 · Before open−6.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck18 slidesSeptember 2026
Technical Presentation (April 2026)Technical16 slidesApril 2026
Cardiovascular Clinical Trialist (CVCT) Forum 2025Conference25 slidesDecember 2025
Technical Presentation (December 2025)Technical11 slidesDecember 2025
Investor Presentation (November 2025)Investor deck45 slidesNov 3, 2025
ASGCT 2025Conference19 slidesMay 2025
ASGCT 2025Conference14 slidesMay 2025
Technical Presentation (February 2025)Technical23 slidesFeb 18, 2025
42nd Annual J.P. Morgan Healthcare Conference 2024Conference30 slidesJan 8, 2024
41st Annual J.P. Morgan Healthcare Conference (January 2023)Conference27 slidesJan 9, 2023
All 14 decks
DeckKindSlidesDate
Merger or Acquisition (September 2022)Merger or acquisition31 slidesSep 30, 2022
PPMD 2019 Annual ConferenceConference23 slidesJun 28, 2019
Parent Project Onlus Annual Conference 2019Conference17 slidesFeb 16, 2019
Investor Presentation (January 2019)Investor deck29 slidesJan 8, 2019

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Announced: about US$200M · US$4.03 a share · Jefferies +3
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), William Blair (co-lead), H.C. Wainwright & Co.
Buyers: Adage Capital Partners LP; Bain Capital Life Sciences; Invus; Perceptive Advisors; RA Capital Management; TCGX; Venrock Healthcare Capital Partners; Vestal Point Capital
Feb 18, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Declared effective by the SEC on Jan 25, 2018. Filed with the SEC to go public on Dec 29, 2017.

Price range
US$18.00 to US$19.00 a share
Shares offered
7,000,000 shares of common stock
Offering size
US$126 million to US$133 million · Shares offered times the price range, worked out by 6ix
Underwriters' option
Up to 1,050,000 more shares
Underwriters
J.P. Morgan, Goldman Sachs & Co. LLC, Leerink Partners, Nomura, Chardan · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceAug 4, 2017
Filed publiclyDec 29, 2017
Amended 3 timesNewest Jan 25, 2018
Shares registered with an exchangeJan 22, 2018
Declared effective by the SECJan 25, 2018
Final prospectus, with the priceNot yet

Filings

FilingFiled
CORRESP · Letter to the SECMar 27, 2026
CORRESP · Letter to the SECMar 27, 2026
UPLOAD · Letter from the SECMar 24, 2026
UPLOAD · Letter from the SECMar 24, 2026
CORRESP · Letter to the SECMay 22, 2025
UPLOAD · Letter from the SECMay 21, 2025
CORRESP · Letter to the SECMar 12, 2025
CORRESP · Letter to the SECMar 12, 2025
UPLOAD · Letter from the SECMar 11, 2025
UPLOAD · Letter from the SECMar 11, 2025
All 43 filings
FilingFiled
CORRESP · Letter to the SECMay 15, 2024
UPLOAD · Letter from the SECMar 18, 2024
CORRESP · Letter to the SECFeb 6, 2024
UPLOAD · Letter from the SECFeb 5, 2024
CORRESP · Letter to the SECFeb 2, 2023
UPLOAD · Letter from the SECFeb 1, 2023
UPLOAD · Letter from the SECAug 25, 2021
CORRESP · Letter to the SECAug 25, 2021
CORRESP · Letter to the SECMar 22, 2021
UPLOAD · Letter from the SECMar 18, 2021
CORRESP · Letter to the SECOct 23, 2019
CORRESP · Letter to the SECOct 11, 2019
UPLOAD · Letter from the SECSep 4, 2019
CORRESP · Letter to the SECMar 15, 2019
UPLOAD · Letter from the SECMar 14, 2019
EFFECT · Notice that a registration is effectiveJan 25, 2018
S-1MEF · Registration of more shares for the same offeringJan 25, 2018
FWP · Free writing prospectusJan 25, 2018
S-1/A · Registration statement, amendedJan 25, 2018
S-1/A · Registration statement, amendedJan 24, 2018
CERT · Exchange's certificate of listingJan 23, 2018
8-A12B · Registration of shares for listing on an exchangeJan 22, 2018
CORRESP · Letter to the SECJan 22, 2018
CORRESP · Letter to the SECJan 22, 2018
CORRESP · Letter to the SECJan 16, 2018
S-1/A · Registration statement, amendedJan 16, 2018
CORRESP · Letter to the SECJan 5, 2018
S-1 · Registration statementDec 29, 2017
DRS/A · Draft registration statement, amendedOct 23, 2017
DRSLTR · Letter to the SEC with a draftOct 20, 2017
UPLOAD · Letter from the SECSep 5, 2017
DRSLTR · Letter to the SEC with a draftAug 4, 2017
DRS · Draft registration statementAug 4, 2017

Open IPO · From the cover of the amended prospectus (S-1/A) filed Jan 25, 2018

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0008.09M13.6M00000
Cost of revenue1.64M2.46M2.58M2.41M2.96M3.92M2.82M1.57M448.0K56.0K
Gross profit-1.64M-2.46M-2.58M8.09M13.6M-3.92M-2.82M-1.57M-448.0K-56.0K
Research and development140.3M96.4M76.6M78.4M58.7M64.9M94.7M58.0M39.9M20.1M
Selling, general and administrative38.9M33.3M27.8M28.9M27.1M21.6M24.6M17.7M15.0M5.46M
Operating income-179.2M-129.7M-104.3M-106.5M-72.3M-88.4M-119.3M-75.7M-54.9M-25.6M
Depreciation and amortization1.64M2.46M2.58M2.41M2.96M3.92M2.82M1.57M448.0K56.0K
EBITDA-177.6M-127.3M-101.7M-104.0M-69.3M-84.5M-116.5M-74.1M-54.4M-25.5M
Interest expense-203.0K340.0K440.0K20.5M66.0K00000
Income before tax-174.2M-124.6M-96.0M-86.0M-72.2M-88.3M-117.2M-74.8M-53.2M-23.8M
Income tax00000000-1.28M-2.60M
Net income-174.3M-124.7M-96.0M-86.0M-72.2M-88.3M-117.2M-74.8M-52.1M-21.5M
Earnings per share, basic-1.99-3.06-4.83-10.10-10.14-25.50-2.91-2.25-2.88-10.14
Earnings per share, diluted-1.99-3.06-4.83-10.10-10.14-25.50-2.91-2.25-2.88-10.14

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents59.9M80.2M74.0M155.4M119.1M154.7M76.0M86.4M52.1M7.68M
Short-term investments128.0M68.7M49.6M58.3M88.6M07.48M36.1M17.0M30.0M
Receivables0110.0K0
Inventory6.01M
Current assets205.5M157.3M129.7M219.6M222.6M158.9M86.3M128.6M70.7M40.0M
Property, plant and equipment4.17M4.75M6.62M9.66M6.46M8.15M11.6M10.4M2.43M452.0K
Total assets232.5M188.7M164.9M260.3M232.4M171.2M103.5M139.6M76.2M40.6M
Accounts payable3.22M4.24M2.03M3.24M4.46M3.27M7.12M3.69M5.07M2.98M
Current liabilities33.5M30.3M14.5M22.5M23.6M24.5M18.3M12.5M11.3M6.87M
Total debt21.2M24.2M26.3M28.5M2.06M5.15M7.07M1.89M
Total liabilities52.5M51.4M38.5M48.6M24.2M39.1M23.4M14.4M11.3M78.5M
Shareholders' equity180.0M137.2M126.5M211.7M208.2M132.1M80.0M125.2M-59.3M-37.9M
Shares outstanding79.0M40.5M20.4M19.6M7.36M84.9M46.0M35.4M046.1M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-156.3M-100.0M-94.2M-98.0M-77.8M-56.6M-92.7M-70.2M-43.2M-20.1M
Capital spending-1.15M-654.0K-1.51M-3.02M-1.28M-899.0K-4.39M-7.78M-2.28M-392.0K
Free cash flow-157.4M-100.7M-95.7M-101.0M-79.0M-57.5M-97.1M-78.0M-45.5M-20.5M
Cash from investing-58.5M-16.1M9.69M59.2M-91.1M6.60M24.5M-26.8M10.4M-4.05M
Cash from financing194.4M122.4M3.12M74.8M135.0M128.7M57.9M131.5M77.1M3.42M
Share buybacks-1.68M-5.11M072.6M134.9M19.3M57.9M131.5M79.5M3.42M
Change in cash-20.3M6.34M-81.4M36.0M-33.9M78.7M-10.3M34.5M44.3M-20.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 6, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 4, 2026Quarterly reportSEC
4 · Change in ownershipOct 26, 2026Insider tradeSEC
4 · Change in ownershipOct 20, 2026Insider tradeSEC
4 · Change in ownershipOct 6, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 6, 2026Current reportSEC
424B5 · ProspectusAug 6, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
S-3ASR · Registration statementAug 6, 2026Offer documentSEC
10-Q · Quarterly reportAug 6, 2026Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 30, 2026Big-stake noticeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 24, 2026Big-stake noticeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
4 · Change in ownershipJun 11, 2026Insider tradeSEC
8-K · Current reportJun 10, 2026Meeting outcomeSEC
424B7 · ProspectusJun 5, 2026Offer documentSEC
10-Q · Quarterly reportMay 12, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 5, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 27, 2026Big-stake noticeSEC
ARS · Annual report to shareholdersApr 23, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2026Meeting noticeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 10, 2026Meeting noticeSEC
8-K · Current reportApr 10, 2026Management or board changeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 1, 2026Other filingsSEC
CORRESP · Letter to the SECMar 27, 2026Other filingsSEC
CORRESP · Letter to the SECMar 27, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 24, 2026Other filingsSEC
UPLOAD · Letter from the SECMar 24, 2026Other filingsSEC
S-3 · Registration statementMar 19, 2026Offer documentSEC
S-3 · Registration statementMar 19, 2026Offer documentSEC
S-8 · Registration statement for employee plansMar 19, 2026Offer documentSEC
10-K · Annual reportMar 19, 2026Annual reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 17, 2026Big-stake noticeSEC
8-K · Current reportMar 11, 2026Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 11, 2026Big-stake noticeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 10, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMar 10, 2026Big-stake noticeSEC
8-K · Current reportMar 6, 2026ResultsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 18, 2026Other filingsSEC
4 · Change in ownershipFeb 18, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeFeb 17, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2026Big-stake noticeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
4 · Change in ownershipFeb 6, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
144 · Notice of proposed saleFeb 4, 2026Other filingsSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
144 · Notice of proposed saleFeb 2, 2026Other filingsSEC
4 · Change in ownershipJan 30, 2026Insider tradeSEC
4 · Change in ownershipJan 13, 2026Insider tradeSEC
144 · Notice of proposed saleJan 13, 2026Other filingsSEC
4 · Change in ownershipJan 7, 2026Insider tradeSEC
4 · Change in ownershipJan 6, 2026Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
4 · Change in ownershipDec 4, 2025Insider tradeSEC
144 · Notice of proposed saleDec 3, 2025Other filingsSEC
4 · Change in ownershipNov 13, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportNov 3, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
4 · Change in ownershipAug 18, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2025Big-stake noticeSEC
4 · Change in ownershipJul 8, 2025Insider tradeSEC
4 · Change in ownershipJun 18, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
4 · Change in ownershipJun 13, 2025Insider tradeSEC
8-K · Current reportJun 13, 2025Management or board changeSEC
S-8 · Registration statement for employee plansJun 13, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 28, 2025Other filingsSEC
CORRESP · Letter to the SECMay 22, 2025Other filingsSEC
UPLOAD · Letter from the SECMay 21, 2025Other filingsSEC
8-K · Current reportMay 15, 2025Current reportSEC
424B5 · ProspectusMay 15, 2025Offer documentSEC
S-3 · Registration statementMay 15, 2025Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2025Big-stake noticeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
SCHEDULE 13G · Big-stake noticeMay 12, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 25, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 25, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 25, 2025Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 17, 2025Big-stake noticeSEC
PRE 14A · Preliminary proxy statementApr 11, 2025Meeting noticeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveMar 17, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveMar 17, 2025Other filingsSEC
4 · Change in ownershipMar 13, 2025Insider tradeSEC
CORRESP · Letter to the SECMar 12, 2025Other filingsSEC
CORRESP · Letter to the SECMar 12, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 11, 2025Other filingsSEC
UPLOAD · Letter from the SECMar 11, 2025Other filingsSEC
S-3 · Registration statementMar 6, 2025Offer documentSEC
S-3 · Registration statementMar 6, 2025Offer documentSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
SCHEDULE 13G · Big-stake noticeFeb 25, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 21, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 21, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedFeb 21, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 21, 2025Insider tradeSEC
4 · Change in ownershipFeb 19, 2025Insider tradeSEC
3 · Initial statement of ownershipFeb 19, 2025Insider tradeSEC
8-K · Current reportFeb 18, 2025Material contractSEC
424B5 · ProspectusFeb 18, 2025Offer documentSEC
FWP · Free writing prospectusFeb 18, 2025Offer documentSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
8-K · Current reportFeb 18, 2025Current reportSEC
8-K · Current reportFeb 18, 2025ResultsSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
144 · Notice of proposed saleFeb 14, 2025Other filingsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 12, 2025Big-stake noticeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC

This page holds 200 of 739 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Solid Biosciences Inc.’s releases · as of Oct 30, 2026

Common shares
111,610,531
Fully diluted
111,610,531

Fully diluted

LineSharesAs of
Common shares111,610,531Oct 30, 2026

Share count over time

CountShares
Oct 30, 2026111,610,531

Open Cap table

Shareholders

Institutions

HolderSharesValueAs of
Ra Capital Management, L.P.12MUS$87MSep 30, 2026
Perceptive Advisors LLC11.9MUS$86.1MSep 30, 2026
Bain Capital Life Sciences Investors, LLC9.81MUS$70.9MSep 30, 2026
Siren, L.L.C.7.69MUS$55.6MSep 30, 2026
Fidelity7.27MUS$52.6MSep 30, 2026
BlackRock6.84MUS$49.4MSep 30, 2026
Rtw Investments, LP5.91MUS$42.7MSep 30, 2026
Vanguard5.34MUS$38.6MSep 30, 2026
Armistice Capital, LLC4.5MUS$32.5MSep 30, 2026
Franklin Templeton4.19MUS$27.3MSep 30, 2026
Show 50 holders
HolderSharesValueAs of
Deep Track Capital, LP3.57MUS$25.8MSep 30, 2026
State Street3.32MUS$24MSep 30, 2026
Ameriprise2.92MUS$21.1MSep 30, 2026
Janus Henderson2.84MUS$20.5MSep 30, 2026
Alyeska Investment Group, L.P.2.38MUS$17.2MSep 30, 2026
Citadel2.1MUS$15.2MSep 30, 2026
Vestal Point Capital, LP2.08MUS$15.1MSep 30, 2026
Redmile Group, LLC1.94MUS$14.1MSep 30, 2026
Geode Capital1.91MUS$13.8MSep 30, 2026
Adage Capital Partners Gp, L.L.C.1.51MUS$10.9MSep 30, 2026
Dimensional1.42MUS$10.2MSep 30, 2026
JPMorgan1.18MUS$8.46MSep 30, 2026
Goldman Sachs1.16MUS$8.37MSep 30, 2026
Morgan Stanley1.15MUS$8.34MSep 30, 2026
Qube Research & Technologies Ltd1.02MUS$7.36MSep 30, 2026
Woodline Partners LP853KUS$6.17MSep 30, 2026
Silverarc Capital Management, LLC760KUS$5.5MSep 30, 2026
Blair William & Co742KUS$5.37MSep 30, 2026
Birchview Capital, LP716KUS$5.18MSep 30, 2026
Moore Capital Management, LP710KUS$5.13MSep 30, 2026
Schwab614KUS$4.44MSep 30, 2026
Northern Trust608KUS$4.39MSep 30, 2026
Ghisallo Capital Management LLC500KUS$3.62MSep 30, 2026
Bank of America456KUS$3.3MSep 30, 2026
Monashee Investment Management LLC410KUS$2.96MSep 30, 2026
Affinity Asset Advisors, LLC400KUS$2.89MSep 30, 2026
Soleus Capital Management, L.P.368KUS$2.66MSep 30, 2026
Susquehanna356KUS$2.57MSep 30, 2026
Invesco321KUS$2.32MSep 30, 2026
Wellington278KUS$2.01MSep 30, 2026
BNY240KUS$1.74MSep 30, 2026
Millennium238KUS$1.72MSep 30, 2026
Nuveen232KUS$1.68MSep 30, 2026
UBS210KUS$1.52MSep 30, 2026
J. Goldman & Co LP185KUS$1.34MSep 30, 2026
Rhumbline Advisers168KUS$1.22MSep 30, 2026
Apis Capital Advisors, LLC160KUS$1.16MSep 30, 2026
Citigroup Inc146KUS$1.05MSep 30, 2026
Alps Advisors Inc142KUS$1.03MSep 30, 2026
AQR Capital Management LLC139KUS$1.01MSep 30, 2026

This page holds 50 of 151 holders. Open Shareholders

Funds

HolderSharesValueAs of
Vanguard Total Stock Market Index Fund3.15MUS$31.5MJun 30, 2026
Select Biotechnology Portfolio2.61MUS$19.1MMay 31, 2026
State Street(R) SPDR(R) S&P(R) Biotech ETF2.58MUS$25.8MJun 30, 2026
iShares Russell 2000 ETF2.05MUS$20.5MJun 30, 2026
Columbia Small Cap Growth Fund1.48MUS$10.8MMay 31, 2026
Franklin Biotechnology Discovery Fund1.41MUS$11.4MJul 31, 2026
Fidelity Small Cap Index Fund863KUS$6.95MJul 31, 2026
Vanguard Extended Market Index Fund774KUS$7.73MJun 30, 2026
Fidelity Advisor Biotechnology Fund678KUS$5.46MJul 31, 2026
iShares Biotechnology ETF552KUS$5.51MJun 30, 2026
Show 50 holders
HolderSharesValueAs of
Fidelity Series Small Cap Core Fund500KUS$4.03MJul 31, 2026
Columbia Small Cap Value Discovery Fund450KUS$3.62MJul 31, 2026
Fidelity Enhanced Small Cap Core ETF428KUS$4.27MJun 30, 2026
iShares Russell 2000 Value ETF374KUS$3.73MJun 30, 2026
iShares Russell 2000 Growth ETF359KUS$3.59MJun 30, 2026
Fidelity Small Cap Discovery Fund341KUS$2.74MJul 31, 2026
Vanguard Russell 2000 Index Fund302KUS$2.22MMay 31, 2026
Dimensional U.S. Small Cap ETF294KUS$2.37MJul 31, 2026
U.S. Small Cap Portfolio287KUS$2.31MJul 31, 2026
Fidelity Series Small Cap Discovery Fund282KUS$2.27MJul 31, 2026
iShares Micro-Cap ETF265KUS$2.64MJun 30, 2026
Fidelity Extended Market Index Fund239KUS$1.75MMay 31, 2026
U.S. Micro Cap Portfolio197KUS$1.59MJul 31, 2026
Schwab Small-Cap Index Fund191KUS$1.54MJul 31, 2026
Invesco Dorsey Wright SmallCap Momentum ETF189KUS$1.39MMay 31, 2026
Master Small Cap Index Series147KUS$1.47MJun 30, 2026
Columbia Variable Portfolio - Small Company Growth Fund120KUS$1.19MJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF111KUS$1.11MJun 30, 2026
Nuveen Small Cap Blend Index Fund104KUS$840KJul 31, 2026
Nuveen Equity Index Fund100KUS$809KJul 31, 2026
Invesco RAFI US 1500 Small-Mid ETF96,703US$779KJul 31, 2026
Fidelity Total Market Index Fund89,704US$658KMay 31, 2026
Direxion Daily S&P Biotech Bull 3X Shares87,747US$707KJul 31, 2026
JPMorgan U.S. Small Company Fund87,707US$876KJun 30, 2026
EQ/2000 Managed Volatility Portfolio85,633US$855KJun 30, 2026
North Square Dynamic Small Cap Fund82,008US$602KMay 31, 2026
Dimensional U.S. Core Equity 2 ETF77,462US$624KJul 31, 2026
Fidelity Series Total Market Index Fund69,647US$511KMay 31, 2026
Fidelity Nasdaq Composite Index Fund58,373US$428KMay 31, 2026
BlackRock Advantage Small Cap Growth Fund56,811US$568KJun 30, 2026
Fidelity Small Cap Value Index Fund56,788US$567KJun 30, 2026
LVIP State Street Small-Cap Index Fund56,300US$562KJun 30, 2026
VIP Disciplined Small Cap Portfolio55,585US$555KJun 30, 2026
Schwab Total Stock Market Index Fund53,125US$428KJul 31, 2026
Vanguard U.S. Momentum Factor ETF50,645US$372KMay 31, 2026
Vanguard Russell 2000 Value Index Fund47,297US$347KMay 31, 2026
Vanguard Institutional Total Stock Market Index Fund47,115US$471KJun 30, 2026
EQ/Small Company Index Portfolio46,880US$468KJun 30, 2026
Virtus Biotech Clinical Trials Etf43,531US$351KJul 31, 2026
U.S. Vector Equity Portfolio43,006US$347KJul 31, 2026

This page holds 50 of 153 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Brooks Gabriel
Officer: Chief Medical Officer
Sale4,374USD 5.62US$24,582Oct 19, 2026

Big stakes

StakeStakeSharesDateFiling
Perceptive Advisors LLC11.20%12MJun 30, 2026Schedule 13D
Ra Capital Management, L.P.10.80%12MNov 4, 2026Schedule 13D
Raymond Debbane9.99%10.1MMar 31, 2026Schedule 13G
FMR LLC7.00%6.88MJun 30, 2026Schedule 13G
BlackRock, Inc.6.50%6.42MJun 30, 2026Schedule 13G
Rtw Investments, LP5.50%5.91MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Rajeev M Shah
Other companies: Freenome, Inc. (Director · Since at least Jul 20, 2026); Parabilis Medicines, Inc. (Director · Since at least Jun 9, 2026); Hemab Therapeutics Holdings, Inc. (Director · Since at least Apr 30, 2026); SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); Evommune, Inc. (Director · Since at least Nov 5, 2025); Sionna Therapeutics, Inc. (Director · Since at least Feb 6, 2025); Septerna, Inc. (Director · Since at least Oct 24, 2024); Bicara Therapeutics Inc. (Director · Since at least Sep 12, 2024); Artiva Biotherapeutics, Inc. (Director · Since at least Jul 18, 2024); Cidara Therapeutics Inc (Director · Since at least Apr 24, 2024); LENZ Therapeutics, Inc. (Director · Since at least Mar 21, 2024); Mineralys Therapeutics, Inc. (Director · Since at least Feb 9, 2023); Acrivon Therapeutics, Inc. (Director · Since at least Nov 9, 2022); ARS Pharmaceuticals, Inc. (Director · Since at least Nov 8, 2022); PepGen Inc. (Director · Since at least May 5, 2022); Nkarta, Inc. (Director · Since at least Feb 14, 2022); Tyra Biosciences, Inc. (Director · Since at least Sep 14, 2021); Wave Life Sciences Ltd. (Director · Since at least Aug 16, 2021); Climb Bio, Inc. (Director · Since at least Aug 9, 2021); Acumen Pharmaceuticals, Inc. (Director · Since at least Jun 30, 2021); Janux Therapeutics, Inc. (Director · Since at least Jun 10, 2021); Vor Biopharma Inc. (Director · Since at least Feb 4, 2021); 89bio Inc (Director · Since at least Nov 8, 2019); Iteos Therapeutics Inc (Director · Jun 9, 2022 – Jun 9, 2022 · Past); Forma Therapeutics Holdings Inc (Director · Jun 8, 2022 – Jun 8, 2022 · Past); Icosavax Inc (Director · Jul 28, 2021 – Feb 19, 2024 · Past); Cytek Biosciences, Inc. (Director · Jul 22, 2021 – Mar 14, 2022 · Past); Jade Biosciences, Inc. (Director · Jun 29, 2021 – Jun 17, 2024 · Past); POINT Biopharma Global Inc (Director · Jun 23, 2021 – Jun 29, 2021 · Past); Werewolf Therapeutics, Inc. (Director · Apr 29, 2021 – May 12, 2025 · Past); Orchard Therapeutics PLC (Director · Feb 9, 2021 – Feb 9, 2021 · Past); Black Diamond Therapeutics, Inc. (Director · Jan 29, 2020 – Jul 5, 2023 · Past); Satsuma Pharmaceuticals Inc (Director · Sep 12, 2019 – Jun 6, 2023 · Past); Eidos Therapeutics Inc (Director · Jun 19, 2018 – May 27, 2020 · Past); Kala Bio, Inc. (Director · Jul 19, 2017 – Jun 17, 2021 · Past); KalVista Pharmaceuticals, Inc. (Director · Nov 21, 2016 – Oct 12, 2017 · Past); Ra Pharmaceuticals Inc (Director · Oct 25, 2016 – Apr 2, 2020 · Past)
Director · Jan 25, 2018 – Jan 11, 2024 · Past
Alexander Cumbo
Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Vor Biopharma Inc. (Chair of the Compensation Committee · Since at least Jul 16, 2025); Climb Bio, Inc. (Director · Since at least Mar 28, 2025); Verve Therapeutics Inc (Director · Since at least Jun 9, 2022); Ra Pharmaceuticals Inc (Director · Nov 14, 2018 – Apr 2, 2020 · Past); Sarepta Therapeutics, Inc. (EVP, Chief Commercial Officer · Mar 5, 2018 – Feb 28, 2020 · Past)
President and CEO, Director · Since at least Dec 2, 2022
Stephen J DiPalma
Other companies: Inozyme Pharma Inc (Interim CFO · May 17, 2021 – May 17, 2021 · Past); Generation Bio Co (See Remarks · Jun 11, 2020 – Jun 11, 2020 · Past); Chemomab Therapeutics Ltd. (Chief Financial Officer · May 1, 2020 – May 1, 2020 · Past); Spero Therapeutics, Inc. (See Remarks · Nov 8, 2019 – Jul 15, 2023 · Past); Interleukin Genetics Inc (Interim CFO · Jul 29, 2016 – Jul 29, 2016 · Past)
Interim CFO · Jan 29, 2021 – Jan 29, 2021 · Past
Lynne Sullivan
Other companies: Inozyme Pharma Inc (Director · Since at least Jul 23, 2020); Unity Biotechnology Inc (CFO & Head of Corp. Dev. · Aug 1, 2020 – Apr 2, 2025 · Past); BiomX Inc. (Director · Nov 4, 2019 – Mar 1, 2023 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past)
Chief Financial Officer at Unity Biotechnology · Since at least Jan 25, 2018
Robert L. Huffines
Other companies: Eikon Therapeutics, Inc. (Director · Since at least Feb 4, 2026); Becton, Dickinson and Company (Director · Since at least Dec 1, 2025); Insulet Corporation (Director · Since at least Oct 23, 2025); Walgreens Boots Alliance Inc (Director · Since at least Jan 25, 2024)
Director · Jun 7, 2022 – Dec 13, 2022 · Past
Ian Smith
Other companies: Odyssey Therapeutics, Inc. (Director · Since at least May 7, 2026); Stoke Therapeutics, Inc. (Chief Executive Officer, Director · Since at least Sep 19, 2023); Foghorn Therapeutics Inc. (Director · Since at least Apr 27, 2021)
Chairman of the Board · Since at least Dec 10, 2020
Sukumar Nagendran
Other companies: Taysha Gene Therapies, Inc. (Director · Since at least Sep 23, 2020); Immunovant, Inc. (Director · May 9, 2019 – May 9, 2019 · Past); AveXis Inc (Sr. VP & Chief Medical Officer · Feb 10, 2016 – May 15, 2018 · Past)
President, Head of Research & Development, Taysha Gene Therapies · Since at least Sep 12, 2018
Bo Cumbo
Other companies: Stoke Therapeutics, Inc. (Director · Since at least Sep 23, 2026); Climb Bio, Inc. (Board Member · Since at least May 14, 2025)
President and CEO · Since at least Jun 2, 2026
Clare Kahn
Other companies: Stoke Therapeutics, Inc. (Director · Since at least Apr 7, 2026)
Board Member · Since at least Nov 5, 2026
Erin Powers Brennan
Other companies: Covetrus Inc (See Remarks · Feb 7, 2019 – Jul 1, 2020 · Past)
Chief Legal Officer, Secretary · Mar 1, 2021 – May 2, 2022 · Past
All 20 people
PersonSeat
Jennifer Lynn Ziolkowski
Other companies: Vigil Neuroscience Inc (Chief Financial Officer, Director · Since at least Jan 6, 2022)
CFO, Treasurer & Asst. Secy · Jan 25, 2018 – Jan 27, 2021 · Past
Kevin Tan
Other companies: Cartesian Therapeutics, Inc. (Chief Financial Officer · Sep 20, 2021 – Jan 3, 2022 · Past)
CFO & Treasurer · Since at least Jan 9, 2023
Martin Freed
Other companies: Dicerna Pharmaceuticals Inc (Director · Jun 14, 2016 – Dec 28, 2021 · Past)
Board Member · Since at least Jun 22, 2018
Carl Ashley MorrisChief Scientific Officer · Jan 25, 2021 – Jan 27, 2023 · Past
David T HowtonChief Operating Officer · Since at least Aug 14, 2025
Gabriel BrooksChief Medical Officer · Since at least Oct 18, 2026
Georgia KerestyBoard Member · Since at least Nov 5, 2026
Ilan GanotDirector · Since at least Jan 25, 2018
Joel Solomon Zev SchneiderChief Operating Officer · Jan 25, 2018 – Mar 14, 2022 · Past
Paul HerzichChief Technology Officer · Since at least Aug 14, 2025

Open People

Log in to ask 6ix AI your own questions about Solid Biosciences Inc.